DIAGOMICS has been acquired by ZytoMax, supported by healthcare specialist Archimed investment firm
The owner of DIAGOMICS has sold the company to ZytoMax GmbH.
Founded in 2009 by Gwénola Tanneau and based in Blagnac, France, DIAGOMICS is a specialized retailer of oncology reagents for in-vitro diagnosis for laboratories, hospitals, clinics and research centers in France, Belgium, Luxemburg, Switzerland, Spain, Tunisia and Morocco. With a highly qualified technical service, the highest level of quality control and an optimal quality-price ratio, DIAGOMICS is recognized as an independent reference in the value-added distribution of support reagents to in-vitro diagnosticians.
Structured in 2021 by Archimed, a global investment firm focused on the healthcare industries, ZytoMax brings together the expertise of three companies, ZytoMed, ZytoVision and 42Life Sciences. Based in Berlin, Germany, ZytoMax specializes in the development, manufacture and distribution of diagnostic reagents and system solutions for immunohistology, in-situ hybridization and molecular pathology. The company employs more than 110 people throughout Europe.
Oaklins’ team in France advised DIAGOMICS, a distributor of oncology reagents, on its affiliation with ZytoMax GmbH.
Gwénola Tanneau
Founder and CEO, DIAGOMICS
Talk to the deal team
Related deals
UKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
Learn moreMedicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Learn moreQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Learn more